SCF ETHNOBIOPROSPECTING WORKFLOW
AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation
PHASE 1 — ETHNOPHARMACOLOGICAL SCOUTING
Phase Code: SCF-CF-AEROVIA201-EBP-P1-0001
Objective: Identify ethnomedical source systems, species, and bioactive classes that can inform development of a localized pulmonary neutrophil elastase modulator for cystic fibrosis.
1.1 Discovery Logic
AEROVIA-201 is not being developed as a crude botanical therapy. It is being developed as a synthetic or semi-synthetic API scaffold informed by natural-product pharmacology.
The Phase 1 ethnobioprospecting goal is to identify source molecules with:
Selection Axis | Required Relevance |
Anti-inflammatory activity | Suppress neutrophil-driven inflammatory amplification |
Tissue-preservation activity | Protect ECM and airway architecture |
Cytokine modulation | Reduce IL-8/TNF/NF-κB inflammatory drift |
Pulmonary compatibility | Support inhaled or lung-localized development |
Safety harmonization | Avoid broad immune suppression |
1.2 Priority Ethnobioprospecting Region
Primary region: Amazon Basin
Rationale: The SCF Amazon Basin database identifies 240 medicinal candidates and ranks species by Quantified Potency Score, with high-priority candidates including immunomodulatory, wound-healing, anti-inflammatory, and cytokine-modulating species.
1.3 Primary Candidate Source Species
Rank | Species | Lead Bioactive Class | Relevant Pharmacology | SCF Role |
1 | Uncaria tomentosa | Oxindole alkaloids | Immunomodulatory | Target Modulator |
2 | Croton lechleri | Taspine / proanthocyanidins | Wound healing, tissue repair | Safety Harmonizer |
3 | Copaifera langsdorffii | Copaiba terpenes / copaiferic acids | Anti-inflammatory | Safety Harmonizer |
4 | Himatanthus sucuuba | Iridoids / iridoid glycosides | Cytokine modulation, anti-inflammatory | Safety Harmonizer |
5 | Mikania glomerata | Diterpenes | Respiratory pharmacology | Pulmonary Support Candidate |
The Amazonian priority list also identifies Uncaria tomentosa, Croton lechleri, Copaifera spp., and Himatanthus sucuuba among the top species recommended for SCF drug discovery, supporting their selection as Phase 1 source candidates.
1.4 Translation to AEROVIA-201
CF Residual Disease Driver | Ethnobioprospecting Translation | API Development Relevance |
Neutrophil elastase excess | Tissue-degradation control | Elastase-binding scaffold search |
ECM destruction | Wound-healing and regenerative botanicals | ECM-preserving pharmacophore logic |
IL-8/NF-κB inflammation | Immunomodulatory botanicals | Anti-inflammatory safety harmonizer profile |
Chronic airway injury | Respiratory-use botanicals | Pulmonary delivery compatibility |
Persistent infection/inflammation loop | Anti-inflammatory + antimicrobial-resistance support | Combination readiness with anti-biofilm agents |
1.5 Phase 1 Candidate Prioritization
Candidate | Priority | Reason |
Croton lechleri / taspine axis | Very High | Strongest tissue-repair and ECM-preservation translation |
Himatanthus sucuuba / iridoid axis | Very High | Cytokine-modulation relevance |
Copaifera spp. / diterpene axis | High | Anti-inflammatory and pulmonary-support potential |
Uncaria tomentosa / oxindole alkaloid axis | High | Immunomodulatory relevance |
Mikania glomerata / diterpene axis | Moderate–High | Respiratory-domain relevance |
1.6 Phase 1 Output
Selected Phase 1 Source Cluster:
Amazonian anti-inflammatory, wound-healing, cytokine-modulating, and respiratory botanicals.
Primary API Development Direction:
Reverse-engineer natural-product anti-inflammatory and tissue-preservation scaffolds into a selective, inhalable neutrophil elastase-modulating API.
Phase 1 Decision:
PROCEED TO PHASE 2 — COMPOUND EXTRACTION & SCF ANALYSIS
MASTER REGISTRY INDEX
SCF-CF-AEROVIA201-EBP-P1-0001 — Phase 1 Ethnopharmacological Scouting
SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator
SCF-ABMD-DB-0001 — Amazon Basin Medicinal Species Database
SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow
SCF-SEF-MD-0001 — SCF Synergistic Evaluation Framework